Omar McTabi, DO
Pulmonary Disease · Grand Junction, CONPI 1932587003
Payments from drug & device makers
Across 41 payments — averaging $136.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$4K
- Jazz Pharmaceuticals Inc.$390
- Inspire Medical Systems, Inc.$307
- GSK$189
- Actelion Pharmaceuticals US, Inc.$132
- Grifols USA, LLC$127
- plus $57 from 1 others
What the payments were for
- Consulting fees$3,91270%
- Travel & lodging$4107%
- Food & beverage$1,07819%
- Education$2084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 16 | $4,408 |
| Jazz Pharmaceuticals Inc. | 3 | $390 |
| Inspire Medical Systems, Inc. | 3 | $307 |
| GSK | 9 | $189 |
| Actelion Pharmaceuticals US, Inc. | 3 | $132 |
| Grifols USA, LLC | 6 | $127 |
| AstraZeneca | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,609 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $667,566 |
| OpsumitMacitentan | 50 | $627,817 |
| UptraviSelexipag | 14 | $348,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 372 | $303,399 |
| Orenitram ErTreprostinil Diolamine | 39 | $169,004 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 103 | $71,522 |
| Fasenra PenBenralizumab | 11 | $63,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $60,154 |
| Ambrisentan | 15 | $54,786 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $53,437 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $51,757 |
| Tadalafil | 20 | $20,152 |
| Spiriva RespimatTiotropium Bromide | 29 | $18,015 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $13,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 172 | $4,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $132 | $975,96764 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $189 | $415,310566 claims |
| AstraZenecaBreztri Aerosphere | $57 | $53,43768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Grand Junction
- David SchwartzAurora$6.7M
- Michael WechslerDenver$3.6M
- David BadeschAurora$2.2M
- Jennifer Taylor CousarDenver$1.4M
- Evans Fernandez PerezDenver$1.3M
- Ronald BalkissoonDenver$1.2M
- Jeffrey SwigrisDenver$845K
- Joshua SolomonDenver$705K
- Thomas WilcoxBoulder$698K
- Marjorie GeorgeDenver$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.